After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull ...

The company’s $3 billion in earnings for the first quarter missed on both top and bottom line, according to BMO Capital ...

Starting in 2025, the Eylea franchise as a whole began to decline due to competitive pressure from long-acting Vabysmo, which competes with Eylea HD, and Pabvlu, a biosimilar version of the original ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) recently saw a big drop in its stock price due to disappointing first-quarter ...

On an adjusted basis, Regeneron earned $8.22 per share in the first quarter, below the average analyst estimate of $8.82, ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

The global Injectable Drug Delivery Market, valued at US$633.7 billion in 2024, is forecasted to grow at a robust CAGR of 8.4 ...

However, the regulatory body issued a complete response letter (CRL) for the Eylea HD pre-filled syringe ... some time now due to competition from Vabysmo. We note that Vabysmo's uptake has ...

Vabysmo keeps expanding market share in all ... growth outside the US as new countries come online and as the prefilled syringe continues to enter into new markets. So overall we think it is ...

Vabysmo continues to gain market share, achieving leadership position in neovascular age-related macular degeneration (nAMD). The product has shown strong uptake of its pre-filled syringe formulation, ...